Systematic review: colitis associated with anti-CTLA-4 therapy.
about
Biological agents in gastrointestinal cancers: adverse effects and their management.Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.Ipilimumab-induced colitis: experience from a tertiary referral center.Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD.Immune checkpoint inhibitors in lung cancer: past, present and future.Immune checkpoint inhibitors side effects and management.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.Ipilimumab-associated colitis or refractory Clostridium difficile infection?Adverse Events in Cancer Immunotherapy.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.Identifying and managing the adverse effects of immune checkpoint blockade.The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature reviewImmune Checkpoint Inhibitor-Associated Colits and Hepatitis
P2860
Q33895581-6CC65CF4-61F9-4681-96B0-DDAB5E553159Q35912366-B9F6BFDF-8A58-455F-8832-C9C367D20B9CQ37019510-CDAABCC2-EFB3-4503-B124-B87B99AE8B4FQ37098427-7AE70CD5-3D3F-4FF3-A5B1-6785662A4367Q37131014-590E85D7-CE80-4C3C-87DB-6AEBDD0008ADQ38739354-B401F68F-413F-4971-9868-9580937F107CQ38791209-96E5CA21-21A1-4C0C-B60B-A0A37A2EED72Q38878899-A25AA66C-CAFD-4170-A910-7BE041B01C9EQ38884560-5191DC73-C60E-40D9-A302-27BAA57D2BF5Q39017623-CD50E1A9-BBB0-4371-9E84-40E8268FE97DQ39328076-7AE7A5AD-1C7D-40EF-B4A9-A1CCC80D3599Q40262479-2B4DE823-E673-424B-89CD-30EE0AB88704Q40400994-047770CD-6BCF-4C22-BF6E-F1338C5B4994Q41110062-B8A3CAD7-0ABD-42C5-A184-E1414C90211DQ46884498-911731E3-AC03-4DC9-A445-CD5A86C3469AQ47102520-A90C9806-4589-4E45-A8B2-2937DA4D89C4Q47397659-63C822F5-57CC-40B4-8916-8B2BA697B90AQ47608535-B0F1EE5D-03DD-4463-97C7-D45D7DB5227CQ48369113-983AE4EA-2B38-442B-86C7-3EF72703E232Q50205173-11B3EE61-54C9-4412-8221-0DF6B0B21246Q52629542-7E2E4C42-45F4-4A09-8E5E-C317B2A26CB7Q52653710-435CAC1F-2836-4A47-A642-C5FB13D45427Q55314300-8C8081A6-F90E-4906-AABF-3029B7F58C2CQ55409972-5A69C0DA-74A1-43B0-8E75-636249A4E2BCQ56889607-FA50552D-194C-4671-919B-9B968E6C8189Q58721137-8CB339D9-9554-4734-82DA-69BFC72044DF
P2860
Systematic review: colitis associated with anti-CTLA-4 therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Systematic review: colitis associated with anti-CTLA-4 therapy.
@en
type
label
Systematic review: colitis associated with anti-CTLA-4 therapy.
@en
prefLabel
Systematic review: colitis associated with anti-CTLA-4 therapy.
@en
P2093
P2860
P356
P1476
Systematic review: colitis associated with anti-CTLA-4 therapy
@en
P2093
P2860
P304
P356
10.1111/APT.13281
P407
P577
2015-06-15T00:00:00Z